Launching a fund used to be a real test of endurance, with timelines often stretching across many months. The process demanded patience that many ambitious founders found difficult to sustain.
Goldman Sachs' Chief Equity Strategist Peter Oppenheimer has called the recent sell-off in U.S. tech stocks a rare 'buying opportunity,' suggesting that the current market conditions may favor investment in this sector.
Allbirds found itself the subject of many jokes on social media on Wednesday. Investors in the long-beleaguered company, though, had something to celebrate. Its stock price shot through the roof after it rebranded itself as NewBird AI and said it would provide GPU compute-as-a-service.
"We were considering multiple forms of capital when we started. It just felt like the opportunity is so large that venture capital gives us the opportunity to take those risks upfront and have the possibility to generate an outsized return."
Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.
Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.
ADIN uses AI to replace the human analysts involved in venture dealmaking. Put in a startup's pitch deck, and out comes a detailed analysis of its business model and founding team, a list of diligence questions and compliance risks, an estimate of the total addressable market, and a suggested valuation. ADIN has about a dozen different agentic investors, each with a distinct persona and investing thesis.
